| scholarly article | Q13442814 |
| P2093 | author name string | He Huang | |
| Yingying Yang | |||
| Yongxian Hu | |||
| P2860 | cites work | Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 |
| CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia | Q29620607 | ||
| Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect | Q34301568 | ||
| How I treat refractory acute GVHD. | Q35828633 | ||
| Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease | Q35904666 | ||
| Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study | Q36141716 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation | Q37390239 | ||
| Mechanistic approaches for the prevention and treatment of chronic GVHD. | Q39002166 | ||
| Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review | Q39106490 | ||
| Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplanta | Q47596812 | ||
| Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. | Q51042672 | ||
| Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) | Q59336540 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| P921 | main subject | ruxolitinib | Q7383611 |
| P304 | page(s) | 139-142 | |
| P577 | publication date | 2019-07-15 | |
| P1433 | published in | Regenerative Therapy | Q50817062 |
| P1476 | title | Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT | |
| P478 | volume | 11 |
Search more.